<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916250</url>
  </required_header>
  <id_info>
    <org_study_id>B7931029</org_study_id>
    <nct_id>NCT03916250</nct_id>
  </id_info>
  <brief_title>Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants</brief_title>
  <official_title>A PHASE 1, SINGLE-CENTER, RANDOMIZED, VEHICLE AND WHITE PETROLATUM CONTROLLED, EVALUATOR BLINDED STUDY TO ASSESS THE SKIN IRRITATION POTENTIAL WITH A RANGE OF CONCENTRATIONS OF PF-06700841 CREAM IN ADULT JAPANESE HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single center, randomized, vehicle and white petrolatum controlled,
      evaluator blinded study to assess the skin irritation potential with a range of
      concentrations of PF-06700841 cream including vehicle and empty patch with white petrolatum
      under occlusive conditions in adult Japanese healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2019</start_date>
  <completion_date type="Actual">May 12, 2019</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants who have skin irritation grade equal to or greater than two plus (++) up to Day 4</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Skin irritation grade is defined as following: no reaction (-); slight erythema (+-); erythema (+); erythema + edema, papules (++); erythema + edema + papules + vesicles (small blisters) (+++) ; large blisters (++++)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants who have skin irritation grade equal to or greater than two plus (++) on each assessment day (Day 3 and Day 4)</measure>
    <time_frame>Day 3 and Day 4</time_frame>
    <description>Skin irritation grade is defined as following: no reaction (-); slight erythema (+-); erythema (+); erythema + edema, papules (++); erythema + edema + papules + vesicles (small blisters) (+++) ; large blisters (++++)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of the maximum skin irritation score reported up to Day 4 by treatment</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Skin irritation score is defined as following: no reaction (0); slight erythema (0.5); erythema (1); erythema + edema, papules (2); erythema + edema + papules + vesicles (small blisters) (3) ; large blisters (4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of the maximum skin irritation score reported up to Day 4 by treatment</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Skin irritation score is defined as following: no reaction (0); slight erythema (0.5); erythema (1); erythema + edema, papules (2); erythema + edema + papules + vesicles (small blisters) (3) ; large blisters (4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of each skin irritation score reported by treatment on each assessment day</measure>
    <time_frame>Day 3 and Day 4</time_frame>
    <description>Skin irritation score is defined as following: no reaction (0); slight erythema (0.5); erythema (1); erythema + edema, papules (2); erythema + edema + papules + vesicles (small blisters) (3) ; large blisters (4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of each skin irritation score reported by treatment on each assessment day</measure>
    <time_frame>Day 3 and Day 4</time_frame>
    <description>Skin irritation score is defined as following: no reaction (0); slight erythema (0.5); erythema (1); erythema + edema, papules (2); erythema + edema + papules + vesicles (small blisters) (3) ; large blisters (4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuation Due to AEs</measure>
    <time_frame>Baseline up to Day 35</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-06700841 cream 0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 cream 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 cream 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 cream 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 cream 3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential</description>
  </arm_group>
  <arm_group>
    <arm_group_label>White petrolatum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841 cream</intervention_name>
    <description>PF-06700841 will be applied topically</description>
    <arm_group_label>PF-06700841 cream 0%</arm_group_label>
    <arm_group_label>PF-06700841 cream 0.1%</arm_group_label>
    <arm_group_label>PF-06700841 cream 0.3%</arm_group_label>
    <arm_group_label>PF-06700841 cream 1%</arm_group_label>
    <arm_group_label>PF-06700841 cream 3%</arm_group_label>
    <other_name>PF-06700841 cream 0% is Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>White petrolatum</intervention_name>
    <description>White petrolatum will be applied topically</description>
    <arm_group_label>White petrolatum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female participants must be 20 to 55 years of age, inclusive, at the time of
             signing the informed consent document.

          -  Body mass index (BMI) of 17.5 to 25 kg/m2; and a total body weight &gt;50 kg (110 lb).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
             allergic disease.

          -  Participants who have any visible skin condition at the application site which, in the
             opinion of the investigative personnel, will interfere with the evaluation of the test
             site reaction.

          -  Participants who have psoriasis and/or active AD/eczema/urticaria.

          -  Participants who have a history of AD.

          -  Participants who have damaged skin in or around the test sites, including sunburn,
             excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous
             freckles, or other disfigurations of the test site.

          -  History of known or suspected intolerance to any of the ingredients of the
             investigational products, adhesive tape/plaster, or the test patches.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OPHAC Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7931029&amp;StudyName=A+PHASE+1%2C+SINGLE-CENTER%2C+RANDOMIZED%2C+VEHICLE+AND+WHITE+PETROLATUM+CONTROLLED%2C+EVALUATOR+BLINDED+STUDY+TO+ASSESS+THE+SKIN+IRRITATION+POTENTIAL+WITH+A+RANGE+OF+CONCENTRATIONS+OF+PF-06700841+CREAM+IN+ADULT+JAPANESE+HEALTHY+PARTICIPANTS</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

